Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma

View through CrossRef
AimWe aimed to investigate the associations between components of the phosphatase and tensin homolog deleted on chromosome 10/protein kinase B/mammalian target of rapamycin (PTEN/AKT/mTOR) pathway and liver cancer stem cell (LCSC) markers, including CD133, CD90, CD44, and epithelial cell adhesion molecule (EpCAM), and to further evaluate the predictive values of these biomarkers for recurrence and survival in hepatocellular carcinoma (HCC).MethodProtein expressions and mRNA levels of PTEN and LCSC markers were determined in 110 HCC tissues and 98 adjacent non‐tumor tissues. Protein expressions of phosphorylated AKT (p‐AKT) and phosphorylated mTOR (p‐mTOR) were detected to evaluate the activation of the PTEN/AKT/mTOR pathway by using immunohistochemistry. Prognostic significance was analyzed by univariate and multivariate analysis.ResultsLoss of PTEN expression was negatively correlated with positive expression of CD133, CD90, and EpCAM (P < 0.05). Positive expression of p‐AKT and p‐mTOR were positively associated with positive expression for CD133, CD90, and EpCAM (P < 0.05). By univariate and multivariate analysis, a higher level of α‐fetoprotein, loss of PTEN expression, and CD133‐positive, p‐AKT‐positive, p‐mTOR‐positive, and EpCAM‐positive signals were predictors for HCC recurrence, whereas advanced TNM stage, loss of PTEN expression, and positive expression of p‐AKT, p‐mTOR, and CD133 were predictors for survival. Patients with PTEN−/CD133+ or PTEN−/EpCAM+ HCC had shorter recurrence‐free survival and overall survival times.ConclusionThe PTEN/AKT/mTOR pathway might play a crucial role in driving recurrence and influencing prognosis in HCC. There could be a potential repressive relationship between components of the PTEN/AKT/mTOR pathway and LCSCs. The combination of PTEN with CD133 or EpCAM expression may serve as a screening tool to monitor recurrence and predict prognosis.
Title: Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma
Description:
AimWe aimed to investigate the associations between components of the phosphatase and tensin homolog deleted on chromosome 10/protein kinase B/mammalian target of rapamycin (PTEN/AKT/mTOR) pathway and liver cancer stem cell (LCSC) markers, including CD133, CD90, CD44, and epithelial cell adhesion molecule (EpCAM), and to further evaluate the predictive values of these biomarkers for recurrence and survival in hepatocellular carcinoma (HCC).
MethodProtein expressions and mRNA levels of PTEN and LCSC markers were determined in 110 HCC tissues and 98 adjacent non‐tumor tissues.
Protein expressions of phosphorylated AKT (p‐AKT) and phosphorylated mTOR (p‐mTOR) were detected to evaluate the activation of the PTEN/AKT/mTOR pathway by using immunohistochemistry.
Prognostic significance was analyzed by univariate and multivariate analysis.
ResultsLoss of PTEN expression was negatively correlated with positive expression of CD133, CD90, and EpCAM (P < 0.
05).
Positive expression of p‐AKT and p‐mTOR were positively associated with positive expression for CD133, CD90, and EpCAM (P < 0.
05).
By univariate and multivariate analysis, a higher level of α‐fetoprotein, loss of PTEN expression, and CD133‐positive, p‐AKT‐positive, p‐mTOR‐positive, and EpCAM‐positive signals were predictors for HCC recurrence, whereas advanced TNM stage, loss of PTEN expression, and positive expression of p‐AKT, p‐mTOR, and CD133 were predictors for survival.
Patients with PTEN−/CD133+ or PTEN−/EpCAM+ HCC had shorter recurrence‐free survival and overall survival times.
ConclusionThe PTEN/AKT/mTOR pathway might play a crucial role in driving recurrence and influencing prognosis in HCC.
There could be a potential repressive relationship between components of the PTEN/AKT/mTOR pathway and LCSCs.
The combination of PTEN with CD133 or EpCAM expression may serve as a screening tool to monitor recurrence and predict prognosis.

Related Results

Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Promoter Methylation and Phosphorylation Status of PTEN in Taiwanese Breast Cancer.
Promoter Methylation and Phosphorylation Status of PTEN in Taiwanese Breast Cancer.
Abstract Background: The PTEN (phosphatase and tensin homolog deleted on chromosome Ten) gene is a novel candidate of tumor suppressor that plays an important role i...
Abstract 136: PTEN phosphatase inhibits metastasis through negatively affecting Entpd5/IGF1R pathway
Abstract 136: PTEN phosphatase inhibits metastasis through negatively affecting Entpd5/IGF1R pathway
Abstract Migration of cancer cell is the key event in metastasis. Recent data suggest that PTEN phosphatase activity may be required for inhibiting cell migration; h...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Role of mTOR in Hematopoiesis and Hematopoietic Stem Cell Regulation.
Role of mTOR in Hematopoiesis and Hematopoietic Stem Cell Regulation.
Abstract Abstract 1490 Poster Board I-513 The mammalian target of rapamycin (mTOR) integrates nutrients, growth factors, and cellular e...
Abstract 1430: CaMKK2 regulates EGF-dependent activation of oncogenic Akt in ovarian cancer cells
Abstract 1430: CaMKK2 regulates EGF-dependent activation of oncogenic Akt in ovarian cancer cells
Abstract Background-The canonical PI3K/Akt pathway is hyperactive in a variety of cancers including ovarian cancer (OVCa). Using baculovirus-expressed, FPLC-purified...

Back to Top